Industry Experts

Shi-Jiang (John) Lu, PhD, MPH, is currently the President and CEO of HebeCell Corporation, focusing on the development and clinical translation of PSC-NK cells for the treatment of cancer, especially metastatic cancer.  He was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which was acquired by Astellas Pharma in 2016.  John is an expert in stem cell biology and regenerative medicine with 30 years of experience. He has been conducting translational research and discovery of novel therapeutic strategies utilizing human pluripotent stem cells (PSC) and their derivatives. Dr. Lu also has more than 10 years of experience in cancer research.  In an analysis of global stem cell patent landscape by Nature Biotechnology in 2014, John’s patent application and citation ranked No. 7 and No. 5, respectively.  John received his BS degree from Wuhan University, MSc from Peking Union Medical College, MPH from Columbia University and PhD from University of Toronto/Ontario Cancer Institute.